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Abstract 
Aims: To evaluate whether the survival rates of patients with heart failure (HF) in the 
community are better than those with a diagnosis of the 4 most common cancers in 
men and women in a contemporary primary care cohort in Scotland. 
Methods and Results: The data were obtained from the Primary Care Clinical 
Informatics Unit from a database of 1.75 million people registered with 393 general 
practices in Scotland. Sex-specific survival modeling was undertaken using Cox 
proportional hazards models, adjusted for potential confounders. A total of 56,658 
patients were eligible to be included in the study with 147,938 person years follow up 
(median follow up 2.04 years). In men, heart failure (reference group; 5yrs survival 
37.7%) had worse mortality outcomes than patients with prostate cancer (HR 0.61, 
95%CI 0.57-0.65; 5yrs survival 49.0%), and bladder cancer (HR 0.88, 95%CI 0.81-
0.96; 5yrs survival 36.5%), but better than lung cancer (HR 3.86, 95%CI 3.65-4.07; 
5yrs survival 2.8%) and colorectal cancer (HR 1.23 95%CI 1.16-1.31; 5 yrs survival 
25.9%). In women, patients with HF (reference group; 5yrs survival 31.9%) had 
worse mortality outcomes than patients with breast cancer (HR 0.55 95%CI 0.51-
0.59; 5yrs survival 61.0%), but better outcomes than lung cancer (HR 3.82, 95%CI 
3.60-4.05; 5yrs survival 3.6%), ovarian cancer (HR 1.98, 95%CI 1.80-2.17; 5yrs 
survival 19%) and colorectal cancer (HR 1.21, 95%CI 1.13-1.29; 5yrs survival 
28.4%).  
Conclusions: Despite advances in management, heart failure remains as ‘malignant’ 
as some of the common cancers in both men and women. 
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Introduction 
 Cardiovascular disease is the commonest cause of death globally, accounting 
for an estimated 17.5 million deaths in 2012 – around a third of all deaths worldwide.1 
Heart failure (HF) represents the end phenotype of many cardiovascular disorders and 
has a prevalence of around 1-2% in the general population, rising to >10% in 
individuals aged 70 years or older. HF is also the commonest cause of hospitalization 
in the over 65s.2 Advances in pharmacological and intra-cardiac device based 
therapies have reduced mortality rates in patients with heart failure by as much as 
50% over the past decade, but both short and long term mortality rates remain 
significant.3-5 The adverse outcomes associated with heart failure have drawn 
comparisons to those of cancer amongst many commentators, including international 
cardiological societies.7 
 Collectively cancer is the second leading cause of morbidity and mortality 
worldwide, with approximately 14 million new cases and 8.2 million cancer-related 
deaths in 2012.8 As with cardiovascular disease, improved treatments over recent 
decades have reduced mortality rates from many cancers.5, A previous comparative 
analysis of patients with a first admission to Scottish hospitals in the UK in 1991 with 
HF and the four most common types of cancer specific to men and women, suggested 
that, with the exception of lung and ovarian cancer, HF had a similar or worse five-
year survival rate than the remaining cancers.9 A comparable analysis of over 1.1 
million hospital admissions in Sweden from 1998-2004 reported similar findings.5 
 Important limitations of these findings include the observation that a first 
hospital admission for many cancers frequently relates to elective surgery or 
investigations 5, whilst that for HF often represents an acute heart failure syndrome.  
These differences will bias survival comparisons towards worse outcomes for HF. 
Furthermore, until now, there has been no attempt to adjusted for comorbid burden,5,9 
which has been increasingly recognised as important confounding factor in this 
patient population that could substantially affect survival.  
Finally, whilst improved survival rates have been reported for patients 
diagnosed with HF and for many cancers over the past decade, that may have 
occurred at different rates in diagnostic groups, past comparisons, therefore, may no 
longer hold. In view of limitations of the previous studies highlighted above, it is 
possible that the survival rates of patients with heart failure in the community are 
significantly better than those with a diagnosis of cancer in contemporary practice, 
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particularly when differences in co-morbid burden are taken into account. We report 
here an analysis of outcome in patients in care cohorts derived from a national 
primary care database in Scotland to investigate whether the often quoted “HF is as 
malignant as cancer” still holds in contemporary practice. 
 
Methods 
Study Design and Setting 
The data for this study were obtained from the Primary Care Clinical 
Informatics Unit (PCCIU).10,11 In brief, PCCIU was founded in 1999 to feedback 
information to practices about aspects of clinical care as part of Royal College of 
General Practitioners Scotland Programme of Clinical Improvement and 
Effectiveness (SPICE). The work involved collecting anonymized clinical 
information bi-annually between 2000 and 2011 from 393 practices across Scotland 
caring for about a third of the Scottish population with data from 1.75 million patients 
and are representative of the Scottish population with a similar spread of age, gender, 
material deprivation and rurality.12 
We carried out a retrospective analysis of PCCIU cohort; our population was 
all adults aged 16 years or older with an incident diagnosis of either heart failure or a 
cancer between 1 April 2002 and 31st March 2011 (the last update of the PCCIU 
dataset). The first three years of PCCIU (1 April 1999 – 30 March 2002) were used to 
mitigate the risk of including prevalent cases: patients with diagnosis codes for either 
heart failure or cancer in this period were excluded. Included cancers were restricted 
to the four most common by gender: prostate, lung, colorectal and bladder cancer for 
men; breast, colorectal, lung and ovarian cancer for women. The Read codes (the 
clinical coding system  used  in  UK  general practice to record patient diagnoses and 
procedures in  health-care  IT  systems) for these diagnoses are given in 
Supplementary Tables 1A and 1B. The primary exposure was first entry of the 
diagnosis of HF or cancer type on the healthcare record, and date of diagnosis was the 
index date. Patients with both a HF and cancer diagnosis present were assigned to the 
cohort of patients with whichever diagnosis was made first. When possible, we based 
our morbidity definitions on Quality Outcomes Framework (QOF)  
(http://qof.digital.nhs.uk/) business rules13 and  read  code  groups  for  long-term  
disorders  (as  defined  by  NHS  Scotland).14 QOF is the world’s largest pay-for-
performance programme. It was introduced for all family practices in 2004, linking up 
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to 25% of family practitioners’ income to performance for more than 100 publicly 
reported quality indicators relating to management of chronic disease, organisation of 
care, and patient experience. A significant proportion of a family practitioners income 
will depend on maintaining a register of patients with a particular diagnosis (such as 
HF and cancer diagnosis) and will also relate to the proportion of such patients that 
receive evidence based care. 
The primary outcome was survival time to all-cause mortality. Potential 
confounders that we accounted for included: age at index diagnosis (continuous 
variable), material deprivation (Scottish index of material deprivation, in quintiles 
with 1= least deprived and 5 = most deprived), rurality (urban/rural index, 6 levels, 
with 1 representing most urban and 6 remote rural), smoking, comorbidities (before 
index date only). These confounders were treated as ever/never terms – i.e. they were 
not time-varying. Comorbidities were initially selected and derived from READ codes 
following Barnett et al.10 A shortlist of these (Hypertension, Depression, Asthma, 
Coronary Heart Disease, Diabetes, Thyroid disease, Rheumatoid Arthritis, COPD, 
Stroke or TIA, Chronic Kidney Disease, Atrial Fibrillation, Peripheral Vascular 
Disease, Epilepsy, Dementia, Schizophrenia, Bronchiectasis, Parkinsons Disease, 
Multiple Sclerosis, Viral Hepatitis, Chronic Liver Disease, Previous Myocardial 
Infarction) was then used for subsequent modeling. Comorbidities diagnosed after the 
index date, and all medications for HF (diuretics, aldosterone receptor antagonists, 
beta blockers, ACE-inhibitors, angiotensin receptor blockers, anti-platelets and lipids) 
were not considered in multivariable models (Supplementary Table 2). Data cleaning 
included removal of patients with missing information on deprivation and rurality, 
and logical conflicts in dates of recorded events. Imputation of deprivation and 
rurality was considered but the proportion of patients missing these fields was low 
(1.94%) and it was felt reasonable to assume that these fields were missing 
completely at random. The majority of the clinical variables were binary indicators of 
presence of a clinical code; the associated condition or medication was assumed to be 
absent if the code was absent. 
 
Statistical Methods 
Descriptive statistics were presented as means with standard deviations, or 
proportions; these were stratified first by gender and then by primary exposure. These 
were compared between exposure groups using ANOVA (to compare means) or Chi 
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squared tests (to compare proportions), with the P-values reported. The number of 
comorbidities was compared between disease groups graphically; survival was 
compared between groups using Kaplan-Meier plots. 
Sex-specific survival modeling was carried out using Cox proportional 
hazards models. Three models were considered: first a univariable model with the 
primary diagnosis only; second a model corrected for demographic variables of age 
and deprivation; and finally a fully adjusted model that corrected for all confounders 
described above - i.e. age, deprivation, rurality, smoking, and all of the comorbidities 
described above that were diagnosed before baseline. Many of these confounders 
described may be highly correlated, which may make their effect sizes and standard 
errors difficult to interpret. However, we do not make any inference about these. We 
did not correct for any medications, as these may act as mediators.  Continuous 
variables such as age were treated as linear. The proportional hazards assumption was 
checked using Schoenfeld residuals.15 All analyses were carried out using R version 
3.0.2.16 
 
Results 
A total of 58,412 patients met the study inclusion criteria from a database of 
1.75 million people registered with 393 medical practices in Scotland. Following 
exclusions of 1754 patients; 3.0% (1119 patients with missing deprivation data and 
635 patients in which date of death was the date of diagnosis, or could not establish 
date of loss to follow up) the final dataset comprised 56,658 patients. There were 
28,064 men and 28,594 women and mean age at first diagnosis was 69.16 (SD 12.76) 
years. Median follow-up was 2.04 years and there were 147,938 person years in total. 
There were 6,795 men with prostate, 4,693 lung, 4,239 colorectal and 2,028 bladder 
cancer, and 10,309 with heart failure. Among the women, 10,760 had breast, 3,610 
colorectal, 3,859 lung and 1,234 ovary cancer, and 9,131 heart failure. 
Descriptive sample characteristics are presented in Table 1 for men and Table 
2 for women. In men, the age at cancer and heart failure diagnoses were similar whilst 
in women heart failure diagnosis occurred later in life than cancer. Patients with heart 
failure, both men and women, had more comorbidities than those with cancer; only 
5.5% of heart failure patients of either gender, had no comorbidity, compared with 20 
to 38% of patients with a diagnosis of cancer. The mean number of comorbid 
conditions was also greater in patients with heart failure compared to those patients 
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diagnosed with cancer. Male patients with heart failure had a mean number of 
comorbidities of 2.62 (SD 1.55), whilst in patients diagnosed with prostate cancer 
(mean 1.47, SD 1.38), lung (1.79, SD 1.56), colorectal (1.52, SD 1.49) and bladder 
cancer (mean 1.71, SD 1.52) mean number of comorbidities were less. Similar 
observations were recorded in women with mean comorbidity number greater in 
patients diagnosed with heart failure (2.8, SD 1.61) than breast (1.19, SD 1.31), 
colorectal (1.52, SD 1.46), lung (1.95, SD 1.6) and ovarian cancer (1.21, SD 1.32). 
The number of comorbidities at index date in each disease and gender group is shown 
in Figures 1a and 1b. 
30-day, one-year and five-year crude mortality rates are also presented in 
Tables 1 and 2.  The largest crude mortality rates occurred in patients with lung 
cancer, with 8.7% of men and 9.3% of women dying within 30 days. The lowest 
crude mortality rates were recorded in women diagnosed with breast cancer (0.5%) 
and men diagnosed with prostate cancer. 30 day mortality rates for men following 
diagnosis with heart failure were 1.5% and 2.2% for women whilst at 1 year mortality 
rates were 14.5% and 17.7% respectively. 
 Kaplan-Meier plots for overall survival in years since diagnosis are presented 
in Figure 2. The main Cox proportional hazards model results are presented in Table 
3. Men with prostate (HR 0.61 95% CI 0.57-0.65, P<0.001) or bladder cancer (HR 0.88 
95% CI 0.81-0.96), P<=0.005) had better survival than those with heart failure, while 
those with lung (HR 3.86 95% CI 3.65-4.07), P<0.001) or colorectal cancer (HR 1.23 
95% CI 1.16-1.31, P<0.001) generally fared worse. Women with breast cancer (HR 0.55 
95% CI 0.51-0.59, P<0.001) had better survival than those with heart failure, while 
those with lung (HR 3.82 95% CI 3.60-4.05, P<0.001), ovarian (HR 1.98 95% CI 1.80-
2.17, P<0.001) or colorectal cancer (1.21 95% CI 1.13-1.29, P<0.001) fared worse.  
All models showed some deviation from proportional hazards. Deviations still 
existed in the fully corrected models, but were minor and so should not affect the 
interpretation of the results (see Supplementary Table 3A and 3B). 
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Discussion 
 Our analysis is the first to compare survival outcomes in a primary care setting 
of patients with a diagnosis of heart failure and the 4 most common cancers in men 
and women in a contemporary cohort of patients treated with current evidence based 
practice that has changed dramatically over the two decades since the older studies 
first reported outcomes following first time hospital admission with a diagnosis of 
heart failure or cancer. Despite advances in care, we found that men and women with 
a diagnosis of heart failure continue to have a worse survival than patients with one of 
several common cancers. Our findings are particularly relevant given that the current 
analysis overcomes many of the limitations of previous work particularly around 
admission bias for different conditions and differences in co-morbid burden between 
the patients with HF and cancer.  
Advances in both the medical and device based treatments, have been 
associated with improved survival rates in patients with HF in many17-20 but not all 
national registry-based studies.21 Age-standardized death rates from heart failure have 
been reported to decrease by 40% in seven European countries between 1987 and 
2008.4 An analysis of all patients in Scotland hospitalised with a first episode of heart 
failure between 1986 and 2003 demonstrated relative declines in short- and medium-
term case-fatality rates of 40-50% in men and 20-25% in women; changes associated 
with significant increases in ACE inhibitor and beta blocker use over this period.17  
 There are limited data regarding longer-term outcomes of incident heart 
failure in the community. Our analysis suggests that mortality rates in patients with 
this condition remain significant. Our observed 1- and 5-year mortality rates of 13% 
and 35% respectively in males, and 15% and 40% in females from time of first 
recorded diagnosis of HF are lower than mortality rates recorded following an acute 
admission to hospital for HF,22,23 probably because the latter population comprise a 
sicker cohort. Our mortality rates were similar to the 5-year mortality rate of 38% 
reported in a contemporary community cohort derived assembled in Ireland following 
a new diagnosis of HF.24 Similarly, the ECHOES community based screening study, 
reported 5-year mortality rates of 38% for those with HF with preserved ejection 
fraction (HFPEF), and 47% with HF with reduced ejection fraction (HFREF)25 
although this was a cross sectional analysis and did not report on survival from time 
of diagnosis. Similarly data derived from Olmsted County reported a 5-year survival 
of 45%, but again was a cross-sectional survival analysis from the time of initiation of 
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the study rather than the time of diagnosis of HF introducing bias towards worse 
outcomes.26 
  HF survival rates, and that of many cancers, have improved over the past 
decade, but these improvements have occurred at different rates in HF and cancer 
populations. For example, an analysis by Stewart et al. of hospital admissions from 
Sweden5 suggested that survival rates for heart failure admissions had improved by a 
greater margin each calendar year than those observed for the cancers studied. Whilst 
our analysis is not subject to many of the limitations of previous analyses such as 
admission bias and failure to adjust for type and number of comorbidities,5,9 our 
findings are remarkably similar to those reported initially by Stewart et al9 and 
subsequently from hospital admission data derived from Sweden.5  This suggests that 
even in a more contemporaneous cohort (by at least a decade) a diagnosis of HF 
remains as ‘malignant’ as that of some cancers. Our findings were broadly consistent 
when the data were stratified by comorbid burden and age of diagnosis. 
 The burden of comorbidity among patients with HF is significant.27 Only 3% 
of patients with HF have no recorded comorbidity whilst up to a third of patients with 
a cancer diagnosis had no comorbid conditions documented in their medical record. 
The number of comorbidities among patients with heart failure appeared to be similar 
in both sexes despite the average age at diagnosis for women with HF being 6 years 
older than that of men. Previous studies have also reported a significant comorbid 
burden in patients with HF and its presence is independently associated with 
increased mortality.28,29  This burden appears to have increased over time.29 In the 
cardiovascular network PRESERVE study undertaken between 2005-2008, less than 
2% of HF patients had no comorbid conditions,30 whilst data derived from the 
Spanish National Heart Failure Registry suggests that only 15% of patients with HF 
have no comorbidity28 whilst only 4% individuals with HF in a Medicare dataset of 
122,630 patients had no non-cardiac comorbid conditions and 40% had five or more 
such comorbidities.31 It is not surprising that the burden of CV comorbidities is 
greatest in patients with HF given that many of them, such as diabetes mellitus, 
hypertension and coronary artery disease are risk factors for the future development 
of HF.32 In contrast, studies of patients with cancer suggest that comorbid burden is 
significantly less.  For instance, perhaps only half of all lung cancer patients have 
comorbidities33 with even less in those with breast 34 ovarian or uterine cancers.34 
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Our data suggest that the burden of CV disease in patients with a diagnosis of 
cancer is also significant, with: 20% of men with a common cancer also having a 
diagnosis of coronary artery disease; 10-20% of either gender diagnosed with 
diabetes; significant rates of previous strokes or transient ischaemic attacks, 
particularly in men; and hypertension prevalence varying from between 30-45% in 
both genders. Previous registry-based studies have also reported significant CV 
comorbidity in patients with lung and prostate cancer.35,36 CV comorbidity and 
estimated CV risk have been independently associated with worse outcomes in 
patients with lung and breast cancer.35,37  
Our study also has several limitations. First, we relied on primary care coding 
to identify the study cohort, with no validation of the codes. Like all other 
observational research undertaken using data derived from electronic health care 
records, PCCIUR relies on clinicians’ observations and entry of relevant codes into 
electronic healthcare records, which may be an incomplete or an inaccurate 
representation of patients’ health. Whilst diagnoses of cancer are generally made by 
specialists based on imaging or biopsy information and hence robust, diagnoses of 
heart failure may be clinical in the first instance and may be less robust particularly in 
the presence of obesity or other conditions associated with dyspnea and edema. 
However the diagnosis of heart failure is well recorded in the United Kingdom 
primary care electronic healthcare records because it is an important part of the 
Quality and Outcomes Framework pay-for-performance scheme which includes 
maintenance of register of patients with a diagnosis of heart failure, and in such 
patients records the percentage of patients with a diagnosis of heart failure which has 
been confirmed by an echocardiogram or by specialist assessment 3 months before or 
12 months after entry onto the register. In Scotland, the percentage of patients with a 
diagnosis of heart failure (diagnosed on or after 1 April 2006) which has been 
confirmed by an echocardiogram or by specialist assessment 3 months before or 12 
months after entering on to the register is over 95%38 suggesting that the diagnosis of 
heart failure is robust. Furthermore, the associated risk factor profile and survival 
rates among the heart failure and cancer cohort are in line with those reported in the 
literature for incident HF and cancer in the community. Second, whilst we were able 
to report on outcomes associated with a heart failure diagnosis we were unable to 
differentiate between heart failure with reduced ejection fraction (HFREF) or heart 
failure with preserved ejection fraction (HFPEF). Previous studies have suggested that 
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patients with HFREF have similar39 or worse short- and long-term mortality outcomes 
compared to those patients with HFPEF40 hence the comparative outcomes of HFREF 
or HFPEF with those of patients with a cancer diagnosis may be different. Third, 
whilst our analysis captures the diagnosis of cancer in the primary care health record, 
it does not provide information relating to the stage of cancer, whether the cancer is 
under remission, whether the cancer was “cured”, or what cancer-related treatments 
were given. Finally, in order to reduce the risk of length time bias and exclude 
prevalent cases of HF or cancer, patients with diagnosis codes for either heart failure 
or cancer during the first three years of PCCIU (1 April 1999 – 30 March 2002) were 
excluded and only those patients registered with the practice for at least 3 months 
prior to their index diagnosis date were included. Nevertheless, we cannot exclude the 
possibility of non-incident cases of either HF or cancer included in the cohort studied, 
although numbers would be small. 
 In conclusion, the current report of over 147,938 person years of observation, 
is the first to compare survival outcomes in a primary care setting of patients with a 
diagnosis of heart failure and the four most common cancers in men and women 
separately.  It has revealed that despite advances in management, heart failure remains 
as ‘malignant’ as some common cancers. Our results highlight the significant multi-
morbidity associated with heart failure that will represent a significant challenge for 
delivery of healthcare in the future, particularly as the burden of heart failure 
continues to grow. Targeted management of the co-morbidities that are common in 
heart failure patient population may be associated with better survival and quality of 
life in this patient population.  
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Figure Legends 
Figure 1a and b: Number of comorbidities by disease group and gender. 
Figure 2: Kaplan-Meier curves of overall survival, separated by gender.  
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Figure 1a and b: Number of comorbidities by disease group and gender. 
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Figure 2: Kaplan-Meier curves of overall survival, separated by gender.  
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Table 1: Baseline and mortality characteristics for men.  
 Prostate Lung Colorectal Bladder HF 
Number of cases 6795 4693 4239 2082 10309 
Age at diagnosis 70.4 (9.1) 69.1 (10.2) 68.3 (11.3) 70.2 (11.3) 70.5 (12.2) 
Date of first 
diagnosis (median) 
2005-12-22 2006-02-13 2006-01-13 2005-11-23 2005-01-
05 
Heart Failure 95 (1.4%) 97 (2.1%) 81 (1.9%) 41 (2%)  
Cancer     226 (2.2%) 
Urban-rural index: 1 
(most urban) 
2151 
(31.7%) 
1749 
(37.3%) 
1429 
(33.7%) 
711 
(35.1%) 
3756 
(36.4%) 
2 2360 
(34.7%) 
1604 
(34.2%) 
1426 
(33.6%) 
722 
(35.6%) 
3255 
(31.6%) 
3 977 (14.4%) 654 (13.9%) 583 (13.8%) 288 
(14.2%) 
1374 
(13.3%) 
4 507 (7.5%) 269 (5.7%) 324 (7.6%) 100 (4.9%) 698 (6.8%) 
5 481 (7.1%) 238 (5.1%) 278 (6.6%) 132 (6.5%) 686 (6.7%) 
6 (most rural) 319 (4.7%) 179 (3.8%) 199 (4.7%) 75 (3.7%) 540 (5.2%) 
Scottish index of 
multiple deprivation  
1 (least deprived) 
1165 
(17.1%) 
551 (11.7%) 608 (14.3%) 332 
(16.4%) 
1266 
(12.3%) 
2 1419 
(20.9%) 
712 (15.2%) 784 (18.5%) 379 
(18.7%) 
1732 
(16.8%) 
3 1401 
(20.6%) 
939 (20%) 862 (20.3%) 394 
(19.4%) 
2162 (21%) 
4 1608 
(23.7%) 
1190 
(25.4%) 
1102 (26%) 516 
(25.4%) 
2708 
(26.3%) 
5 (most deprived) 1202 
(17.7%) 
1301 
(27.7%) 
883 (20.8%) 407 
(20.1%) 
2441 
(23.7%) 
non smoker 2085 
(30.7%) 
153 (3.3%) 942 (22.2%) 377 
(18.6%) 
2368 (23%) 
smoker 913 (13.4%) 661 (14.1%) 430 (10.1%) 384 
(18.9%) 
1757 (17%) 
ex-smoker 2283 
(33.6%) 
1033 (22%) 1345 
(31.7%) 
763 
(37.6%) 
4396 
(42.6%) 
smoking missing 1514 
(22.3%) 
2846 
(60.6%) 
1522 
(35.9%) 
504 
(24.9%) 
1788 
(17.3%) 
Number of 1.47 (1.38) 1.79 (1.56) 1.52 (1.49) 1.71 (1.52) 2.62 (1.55) 
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comorbidities 
No comorbidity 1949 
(28.7%) 
1116 
(23.8%) 
1278 
(30.1%) 
499 
(24.6%) 
562 (5.5%) 
Hypertension 2614 
(38.5%) 
1515 
(32.3%) 
1596 
(37.7%) 
801 
(39.5%) 
4711 
(45.7%) 
Depression 603 (8.9%) 464 (9.9%) 358 (8.4%) 190 (9.4%) 1068 
(10.4%) 
Asthma 491 (7.2%) 355 (7.6%) 286 (6.7%) 124 (6.1%) 788 (7.6%) 
Coronary Heart 
Disease 
1303 
(19.2%) 
1091 
(23.2%) 
817 (19.3%) 488 
(24.1%) 
6295 
(61.1%) 
Diabetes 688 (10.1%) 562 (12%) 611 (14.4%) 314 
(15.5%) 
2234 
(21.7%) 
Thyroid Disease 202 (3%) 139 (3%) 109 (2.6%) 68 (3.4%) 480 (4.7%) 
Rheumatoid Arthritis 584 (8.6%) 358 (7.6%) 382 (9%) 187 (9.2%) 1209 
(11.7%) 
COPD 611 (9%) 1241 
(26.4%) 
390 (9.2%) 237 
(11.7%) 
1707 
(16.6%) 
Stroke TIA 321 (4.7%) 445 (9.5%) 245 (5.8%) 112 (5.5%) 754 (7.3%) 
CKD 550 (8.1%) 473 (10.1%) 381 (9%) 220 
(10.8%) 
1560 
(15.1%) 
AF 238 (3.5%) 168 (3.6%) 162 (3.8%) 106 (5.2%) 552 (5.4%) 
PVD 388 (5.7%) 285 (6.1%) 250 (5.9%) 115 (5.7%) 2519 
(24.4%) 
Epilepsy 295 (4.3%) 508 (10.8%) 231 (5.4%) 149 (7.3%) 1153 
(11.2%) 
Dementia 78 (1.1%) 83 (1.8%) 57 (1.3%) 29 (1.4%) 172 (1.7%) 
Schizophrenia 82 (1.2%) 72 (1.5%) 47 (1.1%) 46 (2.3%) 230 (2.2%) 
Bronchiectasis 31 (0.5%) 60 (1.3%) 27 (0.6%) 14 (0.7%) 86 (0.8%) 
Parkinsons Disease 32 (0.5%) 22 (0.5%) 15 (0.4%) 6 (0.3%) 54 (0.5%) 
Multiple Sclerosis 50 (0.7%) 17 (0.4%) 22 (0.5%) 11 (0.5%) 100 (1%) 
Viral Hepatitis 11 (0.2%) 3 (0.1%) 6 (0.1%) 2 (0.1%) 18 (0.2%) 
Chronic Liver 
Disease 
2 (0%) 4 (0.1%) 2 (0%) 0 (0%) 3 (0%) 
Previous MI 657 (9.7%) 563 (12%) 442 (10.4%) 261 4448 
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(12.9%) (43.1%) 
CABG 416 (6.1%) 239 (5.1%) 233 (5.5%) 127 (6.3%) 1956 (19%) 
Diuretics 2406 
(35.4%) 
1279 
(27.3%) 
1402 
(33.1%) 
699 
(34.5%) 
8189 
(79.4%) 
Aldosterone receptor 
antagonist 
464 (6.8%) 114 (2.4%) 218 (5.1%) 130 (6.4%) 741 (7.2%) 
B-Blockers 1819 
(26.8%) 
733 (15.6%) 1048 
(24.7%) 
580 
(28.6%) 
6307 
(61.2%) 
ACE 1352 
(19.9%) 
451 (9.6%) 704 (16.6%) 396 
(19.5%) 
3634 
(35.3%) 
Angiotensin receptor 
antagonist 
580 (8.5%) 165 (3.5%) 245 (5.8%) 149 (7.3%) 1727 
(16.8%) 
Anti-platelet agents 3014 
(44.4%) 
1565 
(33.3%) 
1600 
(37.7%) 
944 
(46.5%) 
7683 
(74.5%) 
Lipid lowering 
agents 
2889 
(42.5%) 
1184 
(25.2%) 
1516 
(35.8%) 
903 
(44.5%) 
7143 
(69.3%) 
Dead 30 days after 
diagnosis 
25/6759 
(0.4%) 
405/4647 
(8.7%) 
102/4196 
(2.4%) 
22/2017 
(1.1%) 
156/10254 
(1.5%) 
Dead 1 year after 
diagnosis 
439/5862 
(7.5%) 
2879/4255 
(67.7%) 
850/3671 
(23.2%) 
290/1786 
(16.2%) 
1343/9322 
(14.4%) 
Dead 5 year after 
diagnosis 
1442/2829 
(51%) 
3707/3812 
(97.2%) 
1616/2181 
(74.1%) 
621/978 
(63.5%) 
3430/5508 
(62.3%) 
Dead (ever recorded) 
1586/6795 
(23.3%) 
3727/4693 
(79.4%) 
1671/4239 
(39.4%) 
655/2028 
(32.3%) 
3713/10309 
(36%) 
Categorical variables given as number (percentage); continuous variables given as mean (standard 
deviation), unless otherwise stated. 
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Table 2: Baseline and mortality characteristics for women.  
 Breast Colorectal Lung Ovary HF 
Number of cases 
10760 3610 3859 1234 9131 
Age at diagnosis 
61.3 (14.0) 70.0 (13.1) 69.7 (10.7) 62.7 (14.3) 76.4 (11.5) 
Date of first diagnosis 
(median) 
30-11-2005 18-01-2006 20-04-2006 25-10-2005 25-01-2005 
Heart Failure 85 (0.8%) 43 (1.2%) 61 (1.6%) 15 (1.2%)  
Cancer     364 (4%) 
 
Urban-rural index: 1 
(most urban) 
3688 
(34.3%) 
1322 
(36.6%) 
1550 
(40.2%) 
432 (35%) 3354 
(36.7%) 
2 3694 
(34.3%) 
1162 
(32.2%) 
1311 (34%) 407 (33%) 2899 
(31.7%) 
3 1484 
(13.8%) 
475 (13.2%) 471 
(12.2%) 
168 
(13.6%) 
1168 
(12.8%) 
4 655 (6.1%) 256 (7.1%) 198 (5.1%) 83 (6.7%) 690 (7.6%) 
5 727 (6.8%) 217 (6%) 199 (5.2%) 91 (7.4%) 573 (6.3%) 
6 (most rural) 512 (4.8%) 178 (4.9%) 130 (3.4%) 53 (4.3%) 447 (4.9%) 
Scottish index of 
multiple deprivation  
1 (least deprived) 
1542 
(14.3%) 
486 (13.5%) 431 
(11.2%) 
197 (16%) 1197 
(13.1%) 
2 2135 
(19.8%) 
700 (19.4%) 595 
(15.4%) 
242 
(19.6%) 
1453 
(15.9%) 
3 2270 
(21.1%) 
748 (20.7%) 750 
(19.4%) 
271 (22%) 2042 
(22.4%) 
4 2626 
(24.4%) 
866 (24%) 954 
(24.7%) 
274 
(22.2%) 
2293 
(25.1%) 
5 2187 
(20.3%) 
810 (22.4%) 1129 
(29.3%) 
250 
(20.3%) 
2146 
(23.5%) 
non smoker 4129 
(38.4%) 
1168 
(32.4%) 
140 (3.6%) 345 (28%) 3352 
(36.7%) 
Smoker 1646 
(15.3%) 
328 (9.1%) 617 (16%) 145 
(11.8%) 
1027 
(11.2%) 
ex-smoker 2264 (21%) 700 (19.4%) 760 
(19.7%) 
189 
(15.3%) 
2536 
(27.8%) 
smoking missing 2721 
(25.3%) 
1414 
(39.2%) 
2342 
(60.7%) 
555 (45%) 2216 
(24.3%) 
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Number of 
comorbidities 
1.19 (1.31) 1.52 (1.46) 1.95 (1.6) 1.21 (1.32) 2.8 (1.61) 
No comorbidity 
4115 (38.2%) 1024 (28.4%) 769 (19.9%) 
465 
(37.7%) 
500 (5.5%) 
Hypertension 
3259 (30.3%) 1450 (40.2%) 
1451 
(37.6%) 
364 
(29.5%) 
4984 
(54.6%) 
Depression 
1863 (17.3%) 511 (14.2%) 776 (20.1%) 
224 
(18.2%) 
1642 (18%) 
Asthma 945 (8.8%) 296 (8.2%) 386 (10%) 95 (7.7%) 925 (10.1%) 
Coronary Heart 
Disease 
839 (7.8%) 499 (13.8%) 718 (18.6%) 108 (8.8%) 
4367 
(47.8%) 
Diabetes 
786 (7.3%) 425 (11.8%) 421 (10.9%) 89 (7.2%) 
1708 
(18.7%) 
Thyroid Disease 
1173 (10.9%) 465 (12.9%) 474 (12.3%) 
133 
(10.8%) 
1532 
(16.8%) 
Rheumatoid Arthritis 
613 (5.7%) 302 (8.4%) 392 (10.2%) 85 (6.9%) 
1327 
(14.5%) 
COPD 
583 (5.4%) 275 (7.6%) 1118 (29%) 74 (6%) 
1455 
(15.9%) 
Stroke TIA 
445 (4.1%) 237 (6.6%) 382 (9.9%) 58 (4.7%) 
1404 
(15.4%) 
CKD 265 (2.5%) 179 (5%) 228 (5.9%) 37 (3%) 722 (7.9%) 
AF 316 (2.9%) 158 (4.4%) 161 (4.2%) 25 (2%) 2370 (26%) 
PVD 238 (2.2%) 130 (3.6%) 274 (7.1%) 30 (2.4%) 740 (8.1%) 
Epilepsy 136 (1.3%) 39 (1.1%) 49 (1.3%) 23 (1.9%) 149 (1.6%) 
Dementia 190 (1.8%) 75 (2.1%) 98 (2.5%) 13 (1.1%) 448 (4.9%) 
Schizophrenia 96 (0.9%) 38 (1.1%) 36 (0.9%) 8 (0.6%) 103 (1.1%) 
Bronchiectasis 34 (0.3%) 13 (0.4%) 26 (0.7%) 1 (0.1%) 73 (0.8%) 
Parkinsons Disease 39 (0.4%) 12 (0.3%) 13 (0.3%) 4 (0.3%) 63 (0.7%) 
Multiple Sclerosis 50 (0.5%) 10 (0.3%) 10 (0.3%) 6 (0.5%) 19 (0.2%) 
Viral Hepatitis 6 (0.1%) 3 (0.1%) 0 (0%) 0 (0%) 3 (0%) 
Chronic Liver 
Disease 
597 (5.5%) 261 (7.2%) 258 (6.7%) 76 (6.2%) 984 (10.8%) 
Previous MI 
305 (2.8%) 207 (5.7%) 292 (7.6%) 48 (3.9%) 
2665 
(29.2%) 
CABG 88 (0.8%) 62 (1.7%) 94 (2.4%) 13 (1.1%) 690 (7.6%) 
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Diuretics 
3531 (32.8%) 1451 (40.2%) 
1309 
(33.9%) 
422 
(34.2%) 
8010 
(87.7%) 
Aldosterone receptor 
blockers 
320 (3%) 114 (3.2%) 79 (2%) 24 (1.9%) 566 (6.2%) 
B-Blockers 
2165 (20.1%) 840 (23.3%) 550 (14.3%) 
228 
(18.5%) 
4480 
(49.1%) 
ACE 
1358 (12.6%) 489 (13.5%) 337 (8.7%) 93 (7.5%) 
2881 
(31.6%) 
Angiotensin receptor 
antagonist 
805 (7.5%) 261 (7.2%) 174 (4.5%) 57 (4.6%) 
1684 
(18.4%) 
Anti-platelet agents 
2493 (23.2%) 1056 (29.3%) 
1218 
(31.6%) 
225 
(18.2%) 
6326 
(69.3%) 
Lipid lowering agents 
2547 (23.7%) 1061 (29.4%) 994 (25.8%) 
223 
(18.1%) 
5149 
(56.4%) 
Dead 30 day post 
diagnosis  
57/10666 
(0.5%) 
79/3577 
(2.2%) 
354/3826 
(9.3%) 
39/1224 
(3.2%) 
197/9065 
(2.2%) 
Dead 1 year post 
diagnosis 
480/9235 
(5.2%) 
719/3101 
(23.2%) 
2241/3427 
(65.4%) 
295/1105 
(26.7%) 
1441/8121 
(17.7%) 
Dead 5 year post 
diagnosis 
1582/4053 
(39%) 
1337/1867 
(71.6%) 
2920/3030 
(96.4%) 
596/736 
(81%) 
3448/5061 
(68.1%) 
Death (ever recorded) 
1709/10760 
(15.9%) 
1376/3610 
(38.1%) 
2941/3859 
(76.2%) 
611/1234 
(49.5%) 
3747/3131 
(41%) 
Categorical variables given as number (proportion); continuous variables given as mean (standard 
deviation), unless otherwise stated. 
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Table 3: Results of Cox proportional hazards models, separated by gender. 
 
Disease Unadjusted HR (95% 
CI), P 
HR adjusted for age, 
deprivation 
HR, fully adjusted 
Men    
HF 1.0 (ref) 1.0 (ref) 1.0 (ref) 
Prostate 0.64 (0.60,0.68), 
P<0.001 
0.64 (0.61,0.68), 
P<0.001 
0.61 (0.57,0.65), 
P<0.001 
Lung 5.72 (5.46,6.00), 
P<0.001 
6.27 (5.98,6.58), 
P<0.001 
3.86 (3.65,4.07), 
P<0.001 
Colorectal 1.34 (1.26,1.42), 
P<0.001 
1.45 (1.37,1.54),  
P<0.001 
1.23 (1.16,1.31), 
P<0.001 
Bladder 0.96 (0.88,1.04),  
P=0.28 
0.97 (0.89,1.05),  
P=0.46 
0.88 (0.81,0.96), 
P<0.005 
Women    
HF 1.0 (ref) 1.0 (ref) 1.0 (ref) 
Breast 0.34 (0.32,0.36), 
P<0.001 
0.58 (0.55,0.62), 
P<0.001 
0.55 (0.51,0.59), 
P<0.001 
Colorectal 1.05 (0.99,1.12),  
P=0.12 
1.31 (1.23,1.40), 
P<0.001 
1.21 (1.13,1.29), 
P<0.001 
Lung 4.22 (4.01,4.43), 
P<0.001 
5.64 (5.36,5.94), 
P<0.001 
3.82 (3.60,4.05), 
P<0.001 
Ovary 1.46 (1.34,1.59), 
P<0.001 
2.55 (2.33,2.78), 
P<0.001 
1.98 (1.80,2.17), 
P<0.001 
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Supplementary Table 1A: Read Codes used for heart failure diagnosis. 
 
Group Name Read 
Code 
Rubric 
Heart failure G58.. Heart failure 
Heart failure G580. Congestive heart failure 
Heart failure G5800 Acute congestive heart failure 
Heart failure G5801 Chronic congestive heart failure 
Heart failure G5802 Decompensated cardiac failure 
Heart failure G5803 Compensated cardiac failure 
Heart failure G581. Left ventricular failure 
Heart failure G5810 Acute left ventricular failure 
Heart failure G582. Acute heart failure 
Heart failure G58z. Heart failure NOS 
Heart failure G1yz1 Rheumatic left ventricular failure 
Heart failure 662f. New York Heart Association classification - class I 
Heart failure 662g. New York Heart Association classification - class II 
Heart failure 662h. New York Heart Association classification - class III 
Heart failure 662i. New York Heart Association classification - class IV 
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Supplementary Table 1B. Read code for cancer diagnosis. 
 
Group Name Read 
Code 
Rubric 
Cancer / Breast B34.. Malignant neoplasm of female breast 
Cancer / Breast B340. Malignant neoplasm of nipple and areola of female breast 
Cancer / Breast B3400 Malignant neoplasm of nipple of female breast 
Cancer / Breast B3401 Malignant neoplasm of areola of female breast 
Cancer / Breast B340z Malignant neoplasm of nipple or areola of female breast NOS 
Cancer / Breast B341. Malignant neoplasm of central part of female breast 
Cancer / Breast B342. Malignant neoplasm of upper-inner quadrant of female breast 
Cancer / Breast B343. Malignant neoplasm of lower-inner quadrant of female breast 
Cancer / Breast B344. Malignant neoplasm of upper-outer quadrant of female breast 
Cancer / Breast B345. Malignant neoplasm of lower-outer quadrant of female breast 
Cancer / Breast B346. Malignant neoplasm of axillary tail of female breast 
Cancer / Breast B347. Malignant neoplasm, overlapping lesion of breast 
Cancer / Breast B34y. Malignant neoplasm of other site of female breast 
Cancer / Breast B34y0 Malignant neoplasm of ectopic site of female breast 
Cancer / Breast B34yz Malignant neoplasm of other site of female breast NOS 
Cancer / Breast B34z. Malignant neoplasm of female breast NOS 
Cancer / Lung B22.. Malignant neoplasm of trachea, bronchus and lung 
Cancer / Lung B220. Malignant neoplasm of trachea 
Cancer / Lung B2200 Malignant neoplasm of cartilage of trachea 
Cancer / Lung B2201 Malignant neoplasm of mucosa of trachea 
Cancer / Lung B220z Malignant neoplasm of trachea NOS 
Cancer / Lung B221. Malignant neoplasm of main bronchus 
Cancer / Lung B2210 Malignant neoplasm of carina of bronchus 
Cancer / Lung B2211 Malignant neoplasm of hilus of lung 
Cancer / Lung B221z Malignant neoplasm of main bronchus NOS 
Cancer / Lung B222. Malignant neoplasm of upper lobe, bronchus or lung 
Cancer / Lung B2220 Malignant neoplasm of upper lobe bronchus 
Cancer / Lung B2221 Malignant neoplasm of upper lobe of lung 
Cancer / Lung B222z Malignant neoplasm of upper lobe, bronchus or lung NOS 
Cancer / Lung B223. Malignant neoplasm of middle lobe, bronchus or lung 
Cancer / Lung B2230 Malignant neoplasm of middle lobe bronchus 
Cancer / Lung B2231 Malignant neoplasm of middle lobe of lung 
Cancer / Lung B223z Malignant neoplasm of middle lobe, bronchus or lung NOS 
Cancer / Lung B224. Malignant neoplasm of lower lobe, bronchus or lung 
Cancer / Lung B2240 Malignant neoplasm of lower lobe bronchus 
Cancer / Lung B2241 Malignant neoplasm of lower lobe of lung 
Cancer / Lung B224z Malignant neoplasm of lower lobe, bronchus or lung NOS 
Cancer / Lung B225. Malignant neoplasm of overlapping lesion of bronchus and 
lung 
Cancer / Lung B226. Mesothelioma 
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Cancer / Lung B22y. Malignant neoplasm of other sites of bronchus or lung 
Cancer / Lung B22z. Malignant neoplasm of bronchus or lung NOS 
Cancer / 
Prostate 
B46.. Malignant neoplasm of prostate 
Cancer / Bowel B13.. Malignant neoplasm of colon 
Cancer / Bowel B130. Malignant neoplasm of hepatic flexure of colon 
Cancer / Bowel B131. Malignant neoplasm of transverse colon 
Cancer / Bowel B132. Malignant neoplasm of descending colon 
Cancer / Bowel B133. Malignant neoplasm of sigmoid colon 
Cancer / Bowel B134. Malignant neoplasm of caecum 
Cancer / Bowel B135. Malignant neoplasm of appendix 
Cancer / Bowel B136. Malignant neoplasm of ascending colon 
Cancer / Bowel B137. Malignant neoplasm of splenic flexure of colon 
Cancer / Bowel B138. Malignant neoplasm, overlapping lesion of colon 
Cancer / Bowel B139. Hereditary nonpolyposis colon cancer 
Cancer / Bowel B13y. Malignant neoplasm of other specified sites of colon 
Cancer / Bowel B13z. Malignant neoplasm of colon NOS 
Cancer / Bowel B14.. Malignant neoplasm of rectum, rectosigmoid junction and anus 
Cancer / Bowel B140. Malignant neoplasm of rectosigmoid junction 
Cancer / Bowel B141. Malignant neoplasm of rectum 
Cancer / Bowel B142. Malignant neoplasm of anal canal 
Cancer / Bowel B1420 Malignant neoplasm of cloacogenic zone 
Cancer / Bowel B143. Malignant neoplasm of anus unspecified 
Cancer / Bowel B14y. Malignant neoplasm of other sites of rectum, rectosigmoid 
junction and anus 
Cancer / Bowel B14z. Malignant neoplasm of rectum, rectosigmoid junction and anus 
NOS 
Cancer / Ovary B44.. Malignant neoplasm of ovary and other uterine adnexa 
Cancer / Ovary B440. Malignant neoplasm of ovary 
Cancer / Ovary B441. Malignant neoplasm of fallopian tube 
Cancer / Ovary B442. Malignant neoplasm of broad ligament 
Cancer / Ovary B443. Malignant neoplasm of parametrium 
Cancer / Ovary B444. Malignant neoplasm of round ligament 
Cancer / Ovary B44y. Malignant neoplasm of other site of uterine adnexa 
Cancer / Ovary B44z. Malignant neoplasm of uterine adnexa NOS 
Cancer / 
Bladder 
B49.. Malignant neoplasm of urinary bladder                                                                                                                                                                  
Cancer / 
Bladder 
B490. Malignant neoplasm of trigone of urinary bladder                                                                                                                                                       
Cancer / 
Bladder 
B491. Malignant neoplasm of dome of urinary bladder                                                                                                                                                          
Cancer / 
Bladder 
B492. Malignant neoplasm of lateral wall of urinary bladder                                                                                                                                                  
Cancer / 
Bladder 
B493. Malignant neoplasm of anterior wall of urinary bladder                                                                                                                                                 
Cancer / B494. Malignant neoplasm of posterior wall of urinary bladder                                                                                                                                                
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Bladder 
Cancer / 
Bladder 
B495. Malignant neoplasm of bladder neck                                                                                                                                                                     
Cancer / 
Bladder 
B496. Malignant neoplasm of ureteric orifice                                                                                                                                                                 
Cancer / 
Bladder 
B497. Malignant neoplasm of urachus                                                                                                                                                                          
Cancer / 
Bladder 
B498. Local recurrence of malignant tumour of urinary bladder                                                                                                                                                
Cancer / 
Bladder 
B49y. Malignant neoplasm of other site of urinary bladder                                                                                                                                                    
Cancer / 
Bladder 
B49y0 Malignant neoplasm, overlapping lesion of bladder                                                                                                                                                      
Cancer / 
Bladder 
B49z. Malignant neoplasm of urinary bladder NOS                                                                                                                                                              
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Supplementary Table 2. Drug group and search string. 
 
Drug Group Search String 
Diuretic Neo NaClex, Diumide K, Centyl K, Mannitol, aldactide, triam-co, burinex, aridil, moduretic, amil-co, co-amilofruse, burinex, frusene, 
lasilactone, co-flumactone, kalspare, dytide, dyazide, co-triamterzide, navispare, coamilozide, dytac, Amilamont, aldactone, 
spironolactone, inspra, eplerenone, triamterene, amiloride, Lasilactone, Frusene, Burinex A, Co-amilofruse, frusol, rusyde, frusid, froop, 
torem, torasemide, burinex, bumetanide, lasix, frusemide, furosemide, diurexan, xipamide, metenix, metolazone, natrilix, indapamide, 
navidrex, cyclopenthiazide, hygroton, chlorthalidone, chlortalidone, Neo-NaClex, Aprinox, bendroflumethiazide, bendrofluazide  
ARA slocinx, doxadura, rogitine, phentolamine, dibenyline, phenoxybenzamine, hytrin, terazosin, hypovase, prazosin, doralese, baratol, 
indoramin, doxazosin, cardura  
Bblocker Propranolol, Angilol, Syprol, Inderal, Half Inderal, Half Inderal, Bedranol, Beta Prograne, Slo-Pro, Acebutolol, Sectral, Atenix, Atenolol, 
Tenormin, Co tenidone, Kalten, Tenoret, Tenoretic, Beta Adalat, Tenif, Bisoprolol Fumarate, Bisoprolol, Vivacor, Cardicor, Emcor, 
Carvedilol, Eucardic, Celiprolol, Celectol, Esmolol Hydrochloride, Esmolol, Brevibloc, Labetalol Hydrochloride, Labetalol, Trandate, 
Metoprolol Tartrate, Metoprolol, Betaloc, Lopresor, Nadolol, Corgard, Nebivolol, Nebilet, Oxprenolol, Trasicor, Trasidrex, Pindolol, 
Visken, Viskaldix, Sotalol, Beta Cardone, Sotacor, Timolol, Betim, Prestim  
ACE tarka, gopten, trandolapril, triapin, tritace, lopace, rampril, accuretic, accupro, quinil, quinapril, coversyl, perindopril, perdix ,moexipril 
,zestoretic ,lisicostad ,zestril ,carace ,lisinopril ,tanatril ,imidapril ,staril ,fosinopril ,innozide ,innovace, enalapril, vascace, cilazapril, 
capozide, capto co, co-zidocapt, capoten, tensopril, kaplon, Captopril, ecopace  
ARB co-diovan, diovan, valsartan, micardis, telmisartan, olmesartan, olmetec, cozaar, losartan, coaprovel, aprovel, irbesartan, teveten, 
eprosartan, candesartan, amias  
Antiplatelet acetylsalicylic, Aggrastat, Tirofiban, intergrilin, Eptifibatide, Asasantin, Persantin, Dipyridamole, Plavix, Clopidogrel, Nuseals, Nu-Seals, 
Caprin, Angettes, Micropirin, Gencardia, Aspirin, Abciximab, ReoPro  
Lipid Maxepa, Omega-3-Marine Triglycerides, Omacor, Omega-3-Acid Ethyl Esters, Niaspan, Nicotinic, Olbetam, Acipimox, Lopid, 
Gemfibrozil, Supralip, Lipantil, Fenofibrate, Modalim, Ciprofibrate, Bezalip, Bezafibrate, Ezetrol, Ezetimibe, Colestid, Colestipol, 
Questran, Cholestyramine, Colestyramine, Cholestagel, Colesevelam, Inegy, Zocor, simvador, Simvastatin, Crestor, Rosuvastatin, 
Lipostat, Pravastatin, Lescol, Fluvastatin, Atorvastatin, Lipitor  
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Supplementary Table 3A: Hazard non-proportionality (Rho=0 is perfect proportionality) for men. 
 
Disease Rho (p), uncorrected model Rho (p) corrected for age, 
deprivation 
Rho (p), fully adjusted 
HF Ref Ref Ref 
Prostate 0.06 (<0.001) 0.05 (<0.001) 0.07 (<0.001) 
Lung -0.12 (<0.001) -0.12 (<0.001) 0.01 (0.35) 
Bowel -0.08 (<0.001) -0.08 (<0.001) -0.02 (0.02) 
Bladder -0.02 (0.03) -0.02 (0.02) -0.003 (0.72) 
 
Supplementary Table 3B: Hazard non-proportionality (Rho=0 is perfect proportionality) for women. 
 
Disease Rho (p), uncorrected model Rho (p) corrected for age, 
deprivation 
Rho (p), fully adjusted 
HF Ref Ref Ref 
Breast 0.03 (<0.001) 0.04 (<0.001) 0.06 (<0.001) 
Bowel -0.10 (<0.001) -0.09 (<0.001) -0.04 (<0.001) 
Lung -0.12  (<0.001) -0.11 (<0.001) 0.002 (0.81) 
Ovary -0.04 (<0.001) -0.03 (0.004) 0.03 (0.004) 
 
 
